Business
Halozyme Announces CRADA With National Institute of Allergy and Infectious Diseases For Use Of ENHANZE® Drug Delivery Technology
SAN DIEGO, June 25, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a Cooperative Research and Development Agreement (CRADA)
About this update from Halozyme Therapeutics, Inc.
[{"type":"text","content":" SAN DIEGO, June 25, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases' Vaccine Research Center (VRC), part of the National Institutes of Health, enabling the VRC's use of Halozyme's ENHANZE® drug delivery technology to develop subcutaneous formulations of broadly neutralizing antibodies (bnAbs) against HIV for HIV treatment.\nThe two bnAbs selected for the CRADA are VRC07-523LS and N6LS. The VRC will engage in early phase studies in healthy adults investigating the safety, tolerability, dose, and pharmacokinetics of formulating these bnAbs with ENHANZE® for the purpose of optimizing subcutaneous administration of these antibodies. \n\"We are excited to collaborate with NIAID as they seek to develop new therapies that potentially address a large unmet need in the field of HIV treatment and prevention,\" said Dr. Helen Torley, President and CEO of Halozyme. \"This CRADA is an example of the value ENHANZE® can potentially bring to the treatment of infectious diseases, particularly in the early stages of development.\" \nAbout ENHANZE® Technology\nHalozyme's proprietary ENHANZE® drug-delivery technology is based on its patented recombinant human hyaluronidase enzyme (rHuPH20). rHuPH20 has been shown to remove traditional limitations on the volume of biologics that can be delivered subcutaneously (just under the skin). By using rHuPH20, some biologics and compounds that are administered intravenously may instead be delivered subcutaneously. ENHANZE® may also benefit subcutaneous biologics by reducing the need for multiple injections. This delivery has been shown in studies to reduce health care practitioner time required for administration and shorten time for drug administration.\nAbout Halozyme\nHalozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug pegvorhyaluronidase alfa (PEGPH20), applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for the treatment of several cancers and has the potential t...